Navigation Links
ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC

BEVERLY HILLS, Calif., July 29, 2014 /PRNewswire/ -- ImmunoClin Corporation (IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals. The company is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders.  As of August 1, 2014, ImmunoClin Corporation will complete the strategic relocation of its corporate headquarters to Washington, D.C., a key center of North American healthcare and biotechnology industries and related governmental agencies. In addition, the Company's chief operating officer, general counsel, and director, Chad S. Johnson, Esq., who will oversee the principal corporate office, is a decades-long D.C. resident.

"We are excited to move ImmunoClin's head office to Washington, D.C.  The location is attractive for obvious regulatory and business reasons, as we continue to progress our strategic growth plan.  Further, under the oversight of officer and director, Chad Johnson, the Washington office will work seamlessly with our established European headquarters in London, United Kingdom and laboratories in central Paris, France," said Dr. Dorothy Bray, Director, President and CEO of ImmunoClin Corporation.

"Washington, D.C. is a great location for the Company's principal office.  ImmunoClin will join the ranks of the expansive tech and healthcare presence in the D.C. area and be positioned to take advantage of the proximity to and interaction with the federal government, including departments and agencies such as HHS, FDA, NIH, USPHS, and USPTO -- not to mention the impressive public and private educational and research institutions located in greater D.C.," said Chad S. Johnson, Esq., Director, COO and General Counsel.  "I am honored to spearhead the efforts of IMCL from our new D.C. office in conjunction with our international board of directors and scientific advisory board."

About ImmunoClin Corporation

ImmunoClin Corporation is a healthcare company with European headquarters in London, United Kingdom and laboratories in central Paris, France -- and principal corporate office being established in Washington, D.C., USA. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease.  ImmunoClin holds multiple patents and trademarks on a global basis.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.

ImmunoClin Corporation
Dr. Dorothy Bray, Director, President & CEO
Tel: 1.888.267.1175

Investment Inquiries
J. Scott Munro, CFO 
Cell: +1 778-987-4308

SOURCE ImmunoClin Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation Reports Second Quarter 2014 Financial Results
2. China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy
3. United Therapeutics Corporation To Announce Second Quarter 2014 Financial Results Before Market Open On Tuesday, July 29, 2014
4. Collaboration Between Shimadzu Corporation and the MacCoss Lab of Biological Mass Spectrometry, University of Washington
5. A Unique Collaboration of Life Science Leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, has formed Triphase Accelerator Corporation to be an Oncology Development Accele
6. ETEX Corporation announces appointment of Stephen R. La Neve as President and Chief Executive Officer
7. Patient Safety Technologies, Inc. Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $2.22 Per Common Share in Cash
8. Sigma-Aldrich Corporation To Present At 32nd Annual J.P. Morgan Healthcare Conference
9. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
10. Perrigo Company And Elan Corporation plc Receive Irish High Court Approval For Perrigos Proposed Acquisition Of Elan
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) ... USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award recognizes ... with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist of ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
Breaking Biology Technology:
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
(Date:10/26/2015)... and LAS VEGAS , ... Nok Labs , an innovator in modern authentication and ... today announced the launch of its latest version of ... platform enabling organizations to use standards-based authentication that supports ... Nok S3 Authentication Suite is ideal for organizations deploying ...
Breaking Biology News(10 mins):